Clinical trial • Phase III • Neurology
Ambroxol for Parkinson's disease
Phase III trial of Ambroxol for Parkinson's disease. 15 participants.
Overview
- Trial Therapeutic Area
- Neurology
- Trial Disease
- Parkinson's disease
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 14-04-2025
- First CTIS Authorization Date
- 16-07-2025
Trial design
Phase III trial across 2 sites in Netherlands.
- Target Sample Size
- 15
Recruitment
- Planned Sample Size
- 15
- Recruitment Window Months
- 7
Geography
- Total Number Of Sites
- 2
- Total Number Of Participants
- 15
Netherlands
- Earliest CTIS Part Ii Submission Date
- 04-07-2025
- Latest Decision Or Authorization Date
- 16-07-2025
- Processing Time Days
- 12
- Number Of Sites
- 2
- Number Of Participants
- 15
Sites
- Site Name
- Universitair Medisch Centrum Groningen
- Department Name
- Neurology
- Contact Person Name
- Teus van Laar
- Contact Person Email
- t.van.laar@umcg.nl
- Site Name
- CTC Netherlands B.V.
- Department Name
- Research
- Contact Person Name
- Wim Tamminga
- Contact Person Email
- info@ctc-netherlands.com
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Ambroxol
- Active Substance
- Ambroxol
- Modality
- Small molecule
Related trials
Other published trials that may interest you.